Several former employees of biotech hedge fund OrbiMed have alleged that Sam Isaly, the firm’s founder & managing partner, sexually harassed his female colleagues for years, according to an investigation by STAT. Isaly is a 72-year-old investor who has long been revered among the biotech community for his ability to pick stocks. But at OrbiMed, former […]
Biotech
United Therapeutics beats sales, earnings estimates in Q3
Shares in United Therapeutics (NSDQ:UTHR) rose today after the biotech beat expectations on Wall Street with its third quarter results. The Silver Spring, Md.-based company posted profits of $267.3 million, or $6.28 per share, on sales of $445.5 million for the 3 months ended Sept. 30, for bottom-line growth of 71% on sales growth of 9.1% compared […]
Ethics watchdog: Rep. Collins broke rules by advocating for biotech
There’s “substantial reason to believe” that Rep. Chris Collins (R-NY) broke federal law and congressional rules by sharing insider information to spur investment and by meeting with government researchers to advocate for Innate Immunotherapeutics (ASX:IIL) – an Australian biotech that he’s invested in. The Republican lawmaker recruited a number of investors for the company, including Dr. Tom […]
7 medtech stories we missed this week: Oct. 6, 2017
From Intellijoint’s CE Mark to Patrona Medical and Kopis’ new partnership, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Intellijoint CE Mark for flagship hip navigation Intellijoint surgical announced in an Oct. 4 press release that it has received CE Mark for its Intellijoint HIP System in […]
Procept BioRobotics treats first patients in Water II test of surgical robot
Procept BioRobotics announced today that the first patients were treated in its Water II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia. The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients […]
Biotech, pharma chime in over Trump’s move to halt immigration program
On Tuesday, biotech and pharmaceutical companies urged president Donald Trump to reconsider his decision to end former president Barack Obama’s policy protecting undocumented immigrants who arrived in the U.S. as children. Attorney general Jeff Sessions said Tuesday morning that Trump would move to halt the Deferred Action for Childhood Arrivals program in six months, unless […]
Cells can be programmed into living devices: Here’s how
Synthetic biologists at Harvard University have programmed microbial cells into living devices that can produce drugs, fine chemicals and biofuels and detect disease-causing agents. A team of biologists at Harvard’s Wyss Institute for Biologically Inspired Engineering fit cells with artificial molecular machinery that could sense stimuli like toxins in the environment, metabolite levels and inflammatory […]
Bonti kicks off Ph2 trial for neurotoxin pain-reliever
Privately-held biotech Bonti said today that it launched the Lantern clinical program, evaluating its intramuscular neurotoxin injection as a non-opioid pain reliever. The first clinical trial, Lantern-1, is a Phase II study designed to assess the safety and efficacy of EB-001 in patients undergoing elective breast augmentation. Get the full story at our sister site, Drug Delivery […]
Researchers successfully edit 1st human embryo with CRISPR
Scientists have successfully edited genes in a human embryo, correcting a disease-causing mutation to prevent the defect from being inherited. The groundbreaking process, covered in a paper published yesterday in Nature, was confirmed last week by the Oregon Health and Science University, which collaborated with the Salk Institute and Korea’s Institute for Basic Science on […]
NantCell takes on troubled CytRx chemotherapeutic
NantCell, one of controversial biotech entrepreneur Patrick Soon-Shiong’s many businesses, said last week that it inked a deal to acquire CytRx‘s (NSDQ:CYTR) aldoxorubicin cancer drug. The compound has faced several obstacles in clinical trials, including when it missed the primary endpoint of a late-stage clinical trial, failing to help patients with second-line soft tissue sarcoma in […]
Anika inks $350k settlement with former CMO Mascioli, hits $5m milestone
Anika Therapeutics (NSDQ:ANIK) said last week that it agreed to pay former chief medical officer Dr. Stephen Mascioli $350,000 “for all alleged damages and attorneys’ fees.” In return, Mascioli agreed not to pursue legal action against the Bedford, Mass.-based company. Mascioli departed from Anika in January this year, after spending less than a year there. Get […]